3 Undervalued Health Care Providers & Services Stocks for Wednesday, October 09
Discover the top 3 undervalued Health Care Providers & Services stocks for Wednesday, October 09 based on AAII’s Stock Grades.Jenna Brashear
Stock Evaluator: PD-Rx Pharmaceuticals, Inc. (PDRX)
PD-Rx Pharmaceuticals, Inc. PDRX
$3.10
0.00
0.00%
August 27, 2026 9:33:08 AM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing system that provides 10 recordkeeping labels to match the 10 bottle trays as a handling package; and PD-Rx Net, a web-based application designed to track prescriptions filled at the point of care and print prescription labels for prescriptions that are filled onsite. Further, it provides primary care, urgent care, pain management, occupational and orthopedic medicine, bariatric, dental, and other physician dispensing services. The company serves the governmental, commercial, and point-of-care pharmaceutical industry. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is based in Oklahoma City, Oklahoma.
Commentary & Analysis
Financial Summary
| Share Statistics | PDRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.1 | $1,785.4 | 3% |
|
| Shares Out (Mil) | 1.7 | 71.5 | 6% |
|
| Institutional Ownership | na | 86.0% | na |
|
| Float (Mil) | na | 55.7 | na |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 1 | 402 | 4% |
|
| Price Change (52-week) |
12.7% | 78.5% | 57% |
|
| Growth | PDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.7%) | 10.7% | 12% |
|
| Net Income (5yr) | 5.6% | (0.5%) | 48% |
|
| EPS (5yr) | 6.2% | 2.1% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (4.8%) | (17.5%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $1,490 | 12% |
|
| Net Income (TTM) (Mil) | $-0 | $24 | 38% |
|
| EPS (TTM) | ($0.160) | $0.200 | 34% |
|
| Operating Cash Flow (TTM) (Mil) | $1 | $151 | 33% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $9 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $338 | 14% |
|
| Enterprise Value (Q1) (Mil) | $5 | $2,334 | 5% |
|
| Valuation | PDRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.60 | 2.96 | 70% |
|
| P/E | na | 25.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PDRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 29.6% | 27.9% | 35% |
|
| Net Margin | (1.4%) | 1.3% | 29% |
|
| ROA | (21.8%) | 2.2% | 20% |
|
| ROE | (35.4%) | 6.8% | 19% |
|
| Liabilities to Assets | 36.9% | 60.5% | 28% |
|
| F-Score | 2 | 5 | na |
|
PD-Rx Pharmaceuticals, Inc. did not pass any screens on 9/4/2026.
